Vir, GSK In Deal With NHS-Supported AGILE To Evaluate VIR-7832 In Early Treatment Of COVID-19
The trial is due to begin in the first quarter of 2021.
VIR-7832 is a neutralizing COVID-19 antibody that preclinical data suggests has two distinguishing properties. These are an enhanced ability to clear infected cells and the potential to enhance virus-specific T-cell function, which could help treat and/or prevent COVID-19 infection.
The AGILE trial platform will be the first to test VIR-7832 in humans. According to the companies, the AGILE trial platform uses adaptable protocols and statistical models to enable the evaluation of candidate medicines for COVID-19 treatment.
An international team of researchers have found that medications to treat high blood pressure do not affect outcomes among patients hospitalized with COVID-19.